Saint Louis University Center for Vaccine Development is looking for volunteers for a study involving an investigational tuberculosis (TB) vaccine.
Purpose of study:
The currently available tuberculosis vaccine, Bacillus Calmette Guerin (BCG), is a live bacterium (germ) that has been weakened so it does not usually cause illness. Although BCG vaccine has been used in many countries outside the United States for about 60 years, many people who are given it still get TB. A better vaccine to prevent TB is needed.
The investigational vaccine in this study is called AERAS-422. AERAS-422 is a new version of BCG engineered to induce better immune responses than standard BCG vaccines. AERAS-422 has never been studied in humans before but appeared to be safe and better than standard BCG in animal testing. The main purpose of this study is to see if it is safe to give AERAS-422 at a low-dose and a high-dose to healthy adults. Another purpose is to see if giving AERAS-422 to healthy adults will better stimulate responses in their blood that help fight TB.
Payment & Time Commitment